First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

For more on Prasad’s return, go here; for a “Matt’s Take” on Prasad, go here; for the latest on investors’ attitudes toward ...

Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit ...

Stifel raised the firm’s price target on Insmed (INSM) to $145 from $121 and keeps a Buy rating on the shares following FDA’s recent approval of ...